Typhoid Fever - Treatment

Antibiotic Therapy

Empirical Treatment (before susceptibility known)

For empirical therapy, ceftriaxone or azithromycin are preferred over fluoroquinolones in patients returning from the Indian subcontinent or regions where decreased fluoroquinolone susceptibility is common.

Based on Susceptibility Pattern

• Optimal: Ciprofloxacin 500 mg bid PO × 5-7 days, or ceftriaxone 2 g/day IV × 10-14 days
• Alternatives: Azithromycin 1 g/day × 5 days; Amoxicillin 1 g tid × 14 days; Chloramphenicol 25 mg/kg tid × 14-21 days; TMP-SMX 160/800 mg bid × 7-14 days

• Optimal: Ceftriaxone 2 g/d IV × 10-14 days; Ciprofloxacin 500 mg bid × 5-7 days; or Azithromycin 1 g/day × 5 days

Fluoroquinolone resistance is rising sharply, especially among travelers from South/Southeast Asia (Indian subcontinent). Nalidixic acid-resistant strains predict clinical fluoroquinolone failure. (Tintinalli's Emergency Medicine)

• Azithromycin (if susceptible) or Carbapenems (e.g., meropenem for ESBL-producing strains)

Uncomplicated Typhoid - Summary Table (Park's Textbook)

Severe Typhoid Fever

• Glucocorticoids are indicated in patients with severe disease (meningitis/encephalitis or refractory shock):
  • Dexamethasone 3 mg/kg IV loading dose, then 1 mg/kg q6h × 8 doses
  • Alternatively: dexamethasone 8 mg/kg × 1 dose, then 1 mg/kg q6h × 48 hours
• Combine with parenteral antimicrobials (ceftriaxone preferred)
• IV rehydration and blood transfusion if needed from GI losses
• (Sleisenger & Fordtran's GI and Liver Disease; Tintinalli's)

Complications Requiring Specific Management

Supportive Treatment

• Oral or IV rehydration
• Antipyretics (paracetamol - avoid NSAIDs/aspirin)
• Nutritional support - soft low-residue diet during acute illness
• Isolation until 3 consecutive negative stool/urine cultures
• Follow-up cultures 3-4 months and 12 months post-discharge to detect carrier state

Drug Resistance - Key Points

• MDR S. Typhi: Resistant to chloramphenicol, ampicillin, TMP-SMX - common in South Asia and Africa
• DCS/Fluoroquinolone-resistant (H58 clone): Rising globally; do NOT use fluoroquinolones empirically for travel-related cases from Indian subcontinent
• XDR S. Typhi: Pakistan-dominant since 2016; ESBL-producing; only azithromycin and carbapenems remain reliable
• Azithromycin resistance is now emerging in countries using it as first-line therapy

Mortality

• Untreated: 10-30%
• With prompt appropriate antibiotic therapy: <1%
• Overall case-fatality rate: ~2.5%; hospitalized patients: ~4.5%

Typhoid Fever - Duration of Treatment

By Drug and Susceptibility Pattern

Key Points on Duration

1. Fluoroquinolones have the shortest course (5-7 days) for fully susceptible strains because of excellent intracellular penetration and bioavailability. For MDR strains, this extends to 7-14 days.
2. Ceftriaxone always requires 10-14 days regardless of susceptibility pattern, because it does not achieve high intracellular concentrations.
3. Azithromycin is effective at 5 days for susceptible strains; extended to 7 days for resistant strains. It concentrates well intracellularly, which shortens the needed course.
4. Older drugs (chloramphenicol, amoxicillin, TMP-SMX) require longer courses of 14-21 days due to slower bactericidal activity and higher relapse rates.
5. Oral cefixime requires 7-14 days but carries a higher risk of clinical failure and slower defervescence compared to fluoroquinolones.
6. Severe typhoid (with dexamethasone): parenteral antibiotics are continued for the full duration (10-14 days with ceftriaxone), with dexamethasone given only for the first 48 hours.

Carrier State Treatment

• Ampicillin/amoxicillin 4-6 g/day + probenecid 2 g/day: 6 weeks
• Achieves eradication in ~70% of carriers
• If gallstones are present: cholecystectomy + concomitant antibiotic therapy

Clinical Note

• Antibiotic resistance
• Focal complications (abscess, perforation)
• Relapse (occurs in ~5-10% of cases, usually 2-3 weeks after completing treatment)